Sold under the brand name Rezdiffra, this medication was approved on March 14, 2024, for the treatment of nonalcoholic steatohepatitis or NASH (since renamed to metabolic dysfunction-associated steatohepatitis or MASH) with moderate to advanced liver scarring
J., Malekzadeh, A., et al
It appears to exhibit high selectivity for the growth hormone secretagogue receptor (GHS-R1a), a receptor also implicated in appetite regulation and energy balance
But it also means there is no regulatory agency routinely inspecting these vendors, testing their products, or enforcing quality standards
It is not FDA-approved, and no medical or healthcare use is suggested
Patients should be monitored for tolerability during dose titration, and bile duct stones remain a rare possibility even without a gallbladder